11th ANNUAL “COMEDY FOR A CURE” Raises Thousands for Tuberous Sclerosis Alliance
Over $200,000 Raised in the Fight for a Cure Against Devastating Genetic Disorder
11th Annual “Comedy For a Cure” took place at Hollywood’s iconic Roosevelt Hotel Sunday night, bringing in thousands of dollars for the Tuberous Sclerosis Alliance (TSC), an organization founded in 1974 by parents of children with TSC who saw the need to educate the public and medical community about the disorder. Hosted by “MadTV” alum and current “Parks & Recreation” star Mo Collins, headlining the event was an array of comedy’s finest, including Australian funnyman Jim Jeffries, radio personality and “Celebrity Apprentice” star Adam Carolla, and “America’s favorite dying lounge act” The Lampshades, featuring Kate Flannery (“The Office”) and Scot Robinson. In addition to the comedy, guests were treated to a night to remember with a silent auction, a special honoring of Beth Lewin, Vice President of Epilepsy, Lundbeck, and words from TSA CEO Kari Luther Rosbeck. The organization was able to raise over $200,000 throughout the entire “Comedy For a Cure” event. “We are incredibly moved by the generosity and partnership of our ‘Comedy for a Cure’ supporters,” commented Rosbeck. “This event has an extraordinary impact on our ability to fund the critical research making a difference for those living with Tuberous Sclerosis Complex.”
It is estimated that every twenty minutes a child is born with Tuberous Sclerosis, a genetic disorder that causes tumors to form in vital organs such as the brain, heart, skin, kidneys, eyes and lungs. Serious health problems include epilepsy, autism, heart disease, facial disfigurement, kidney failure, lung disease, and even death, and because TSC is the leading genetic cause of epilepsy and autism, every dollar raised to find a cure and better treatments for TSC can also mean a better understanding of epilepsy, autism, and even cancer – diseases that touch most everyone all of us know and love. Today, the Tuberous Sclerosis Alliance is able to provide its constituents with the most up-to-date information about the disorder while awarding grants for research that will eventually result in a cure.
For more information about the TS Alliance or TSC, please visit www.tsalliance.org. For press inquiries, materials, and information, contact RJ Rousso (email@example.com) or John Filizzola (firstname.lastname@example.org) at RFPR, Inc. at 323-933-4646.